1.Clinicopathologic Characteristics of IgA Nephropathy with Crescents.
Yanggyun KIM ; Taewon LEE ; Sangho LEE ; Kyunghwan JEONG ; Juyoung MOON ; Chungyoo IHM
Korean Journal of Nephrology 2011;30(2):148-154
PURPOSE: In IgA nephropathy (IgAN), crescent formation appears to represent a nonspecific response to severe injury to the glomerular capillary wall. This study was performed to evaluate the clinicopathological manifestations of the crescents and their effects on the clinical courses of IgAN. METHODS: The patients diagnosed IgAN were included and the information about their renal biopsies, chemistries and immunohistochemistry findings were collected retrospectively. Some patients that have similar renal function and protenuria were followed up for 12 months to examine the effects of crescents on the renal prognosis. RESULTS: 38 patients with crescents and 177 patients without crescents were enrolled. The patients with IgAN with crescents showed significantly lower renal function (MDRD eGFR 58.5 vs 88.4 ml/min/1.73m2), higher blood pressure, larger amount of proteinuria and more severe hematuria than those patients without crescents. In pathologic findings, HS Lee grades were higher (2.9 vs 1.9). When we selected patients with mildly decreased renal function (serum creatinine <2.5 mg/dL, PCR 0.5-8 g/gCr), the patients with crescents presented lower renal function and higher proteinuria but no statistical significance. After 12 months of treatment, the patients with crescents showed significantly lower renal function (MDRD eGFR 78.6 vs 96.5 ml/min/1.73m2) and higher proteinuria (0.9 vs 0.6 g/gCr). CONCLUSION: The patients with IgAN with crescents showed more deteriorated clinicopathological findings than those without crescents. Despite aggressive treatments, they presented a significantly decreased renal function and larger amount of proteinuria after 1 year. So crescents are supposed to have poor effects on the clinical course.
Biopsy
;
Blood Pressure
;
Capillaries
;
Creatinine
;
Glomerulonephritis, IGA
;
Hematuria
;
Humans
;
Immunoglobulin A
;
Immunohistochemistry
;
Polymerase Chain Reaction
;
Proteinuria
;
Retrospective Studies
2.Association of Polymorphisms in Monocyte Chemoattractant Protein-1 Promoter with Diabetic Kidney Failure in Korean Patients with Type 2 Diabetes Mellitus.
Ju Young MOON ; Laeik JEONG ; Sangho LEE ; Kyunghwan JEONG ; Taewon LEE ; Chun Gyoo IHM ; Jungho SUH ; Junghee KIM ; Yoo Yeon JUNG ; Joo Ho CHUNG
Journal of Korean Medical Science 2007;22(5):810-814
Monocyte chemoattractant protein-1 (MCP-1) is suggested to be involved in the progression of diabetic nephropathy. We investigated the association of the -2518 A/G polymorphism in the MCP-1 gene with progressive kidney failure in Korean patients with type 2 diabetes mellitus (DM). We investigated -2518 A/G polymorphism of the MCP-1 gene in type 2 DM patients with progressive kidney failure (n=112) compared with matched type 2 DM patients without nephropathy (diabetic control, n=112) and healthy controls (n=230). The overall genotypic distribution of -2518 A/G in the MCP-1 gene was not different in patients with type 2 DM compared to healthy controls. Although the genotype was not significantly different between the patients with kidney failure and the diabetic control (p=0.07), the A allele was more frequent in patients with kidney failure than in DM controls (42.0 vs. 32.1%, p=0.03). The carriage of A allele was significantly associated with kidney failure (68.8 vs. 54.5%, OR 1.84, 95% CI 1.07-3.18). In logistic regression analysis, carriage of A allele retained a significant association with diabetic kidney failure. Our result shows that the -2518 A allele of the MCP-1 gene is associated with kidney failure in Korean patients with type 2 DM.
Adult
;
Aged
;
Alleles
;
Chemokine CCL2/*metabolism
;
Diabetes Mellitus, Type 2/ethnology/*genetics/*metabolism
;
Diabetic Nephropathies/ethnology/*genetics/*metabolism
;
Female
;
Genotype
;
Humans
;
Kidney Failure
;
Korea
;
Male
;
Middle Aged
;
*Polymorphism, Genetic
;
*Promoter Regions, Genetic
;
Risk Factors
3.A Case of Imipenem Resistance Acinetobacter baumannii Peritonitis Successfully Treated with Colistin Therapy.
Kyuseong LIM ; Jina PAK ; Juyoung MOON ; Kyunghwan JEONG ; Sangho LEE ; Taewon LEE ; Chun Gyoo IHM ; Myung Jae KIM
Korean Journal of Nephrology 2008;27(3):402-406
Peritonitis in continuous ambulatory peritoneal dialysis (CAPD) is a major cause of technical failure in peritoneal dialysis. The major pathogen is gram positive bacteria, and other main pathogens include gram negative bacteria, mixed microorganisms and fungi. The case of imipenem resistance Acinetobacter baumannii (IRAB) peritonitis are not common. We report a case of peritonitis by IRAB that was not responsive to the empirical antibiotics for CAPD-associated peritonitis. A 56-year-old male with a CAPD catheter inserted 2 weeks before visited our hospital for abdominal pain and turbid peritoneal fluid. He had been diagnosed as having an end stage renal disease (ESRD) about a month before. White blood cell and neutrophil count were elevated at the initial peritoneal fluid analysis, so we diagnosed him as having CAPD-associated peritonitis. Antibiotic therapy was initiated with intraperitoneal injections of ceftazidime/cefamezine which were soon changed to vancomycin/ceftazidime. However, vancomycin/ceftazidime regimen proved ineffective. On the fifth and sixth hospital day, IRAB was cultured from the CAPD catheter exit site swab and peritoneal fluid sampled on the first visiting day. Accordingly, we changed the antibiotics to colistin and removed the CAPD catheter, which led to clinical and laboratory improvement. In the cases of CAPD associated peritonitis in patients who have a history of ICU stay, exposure to the 3rd generation cephalosporin or imipenem, or who are elderly, we must suspect unusual pathogen or multi-drug resistance pathogen such as IRAB.
Abdominal Pain
;
Acinetobacter
;
Acinetobacter baumannii
;
Aged
;
Anti-Bacterial Agents
;
Ascitic Fluid
;
Catheters
;
Colistin
;
Drug Resistance, Multiple
;
Fungi
;
Gram-Negative Bacteria
;
Gram-Positive Bacteria
;
Humans
;
Imipenem
;
Injections, Intraperitoneal
;
Kidney Failure, Chronic
;
Leukocytes
;
Male
;
Middle Aged
;
Neutrophils
;
Peritoneal Dialysis
;
Peritoneal Dialysis, Continuous Ambulatory
;
Peritonitis
4.Cholangiocarcinoma Masquerading as IgG4-related Sclerosing Cholangitis.
Sangyoung YI ; Dong Hui CHO ; Seungha HWANG ; Kyunghwan OH ; Hyeon Jeong KIM ; Jihun KIM ; Myung Hwan KIM
Korean Journal of Pancreas and Biliary Tract 2016;21(3):168-173
IgG4-related sclerosing cholangitis (IgG4-SC) represents a rare but clinically challenging differential diagnosis in patients with biliary strictures which can be mistaken for cholangiocarcinoma. We present a case of a 73-year-old male presented with abdominal discomfort and weight loss. Biliary images showed long-segment luminal narrowing of extrahepatic bile duct associated with prominent enhanced wall thickening, but luminal patency was preserved. Pancreatic images revealed segmental irregular narrowing of main pancreatic duct without upstream duct dilatation. His liver function tests and CA19-9 level were normal. Putting all findings together, IgG4-SC associated with autoimmune pancreatitis was strongly suspected. However, endobiliary biopsy of extrahepatic bile duct revealed adenocarcinoma which was not resectable due to celiac axis involvement. Because there is an overlap in biliary imaging findings between IgG4-SC and cholangiocarcinoma, biopsy is essential for adequate differential diagnosis. We present a case of cholangiocarcinoma masquerading as IgG4-SC based on clinical and imaging findings.
Adenocarcinoma
;
Aged
;
Bile Ducts, Extrahepatic
;
Biopsy
;
Cholangiocarcinoma*
;
Cholangitis, Sclerosing*
;
Constriction, Pathologic
;
Diagnosis, Differential
;
Dilatation
;
Humans
;
Liver Function Tests
;
Male
;
Pancreatic Ducts
;
Pancreatitis
;
Phenobarbital
;
Weight Loss
5.Computational Flow Dynamics of the Severe M1 Stenosis Before and After Stenting.
Dae Chul SUH ; Young Bae KO ; Sung Tae PARK ; Kyunghwan YOON ; Ok Kyun LIM ; Jin Sun OH ; Yun Gyeong JEONG ; Jong Sung KIM
Neurointervention 2011;6(1):13-16
PURPOSE: Computational flow dynamic (CFD) study has not been widely applied in intracranial artery stenosis due to requirement of high resolution in identifying the small intracranial artery. We described a process in CFD study applied to symptomatic severe intracranial (M1) stenosis before and after stenting. MATERIALS AND METHODS: Reconstructed 3D angiography in STL format was transferred to Magics (Materialise NV, Leuven, Belgium) for smoothing of vessel surface and trimming of branch vessels and to HyperMesh (Altair Engineering Inc., Auckland, New Zealand) for generating tetra volume mesh from triangular surface-meshed 3D angiogram. Computational analysis of blood flow in the blood vessels was performed using the commercial finite element software ADINA Ver 8.5 (ADINA R & D, Inc., Lebanon, MA). The distribution of wall shear stress (WSS), peak velocity and pressure in a patient was analyzed before and after intracranial stenting. RESULTS: Computer simulation of wall shear stress, flow velocity and wall pressure before and after stenting could be demonstrated three dimensionally by video mode according to flow vs. time dimension. Such flow model was well correlated with angiographic finding related to maximum degree of stenosis. Change of WSS, peak velocity and pressure at the severe stenosis was demonstrated before and after stenting. There was no WSS after stenting in case without residual stenosis. CONCLUSION: Our study revealed that CFD analysis before and after intracranial stenting was feasible despite of limited vessel wall dimension and could reveal change of WSS as well as flow velocity and wall pressure.
Angiography
;
Arteries
;
Atherosclerosis
;
Blood Vessels
;
Cerebral Arteries
;
Characidae
;
Computer Simulation
;
Constriction, Pathologic
;
Glycosaminoglycans
;
Humans
;
Lebanon
;
Magic
;
Stents
6.Complete Hematologic Response and Cytogenetic Remission after Imatinib and Dexamethasone Treatment of a Ph+ Precursor B-cell Acute Lymphoblastic Leukemia in Renal Transplantation Patient.
Sun Kyung BAEK ; Kyung Sam CHO ; Byung Hyuk YANG ; Si Young KIM ; Hwi Joong YOON ; Kyunghwan JEONG ; Chun Gyoo IHM
Korean Journal of Hematology 2009;44(1):62-66
In this report, we present a case of a patient with Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia after renal transplantation. The patient, a 65-year-old man, had received a kidney transplantation 20 years prior to diagnosis with Ph+ precursor B-cell ALL. Because he was refractory to intensive chemotherapy and had refused to receive additional intensive chemotherapy, he was treated with imatinib and dexamethasone. While this patient experienced a complete hematologic and cytogenetic response, he did not show a complete molecular remission. Eighty days after imatinib combination therapy, the patient relapsed and died from intracerebral hemorrhage.
Aged
;
B-Lymphocytes
;
Benzamides
;
Cerebral Hemorrhage
;
Cytogenetics
;
Dexamethasone
;
Humans
;
Kidney Transplantation
;
Philadelphia
;
Philadelphia Chromosome
;
Piperazines
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma
;
Precursor Cells, B-Lymphoid
;
Pyrimidines
;
Imatinib Mesylate
7.Factors associated with successful response to neurolytic celiac plexus block in patients with upper abdominal cancer-related pain: a retrospective study
Hyun-Jung KWON ; Kyunghwan JANG ; Jeong-Gil LEEM ; Jin-Woo SHIN ; Doo-Hwan KIM ; Seong-Soo CHOI
The Korean Journal of Pain 2021;34(4):479-486
Background:
Prior studies have reported that 40%-90% of the patients with celiac plexus-mediated visceral pain benefit from the neurolytic celiac plexus block (NCPB), but the predictive factors of response to NCPB have not been evaluated extensively. This study aimed to identify the factors associated with the immediate analgesic effectiveness of NCPB in patients with intractable upper abdominal cancer-related pain.
Methods:
A retrospective review was performed of 513 patients who underwent NCPB for upper abdominal cancer-related pain. Response to the procedure was defined as (1) a decrease of ≥ 50% or ≥ 4 points on the numerical rating scale (NRS) in pain intensity from the baseline without an increase in opioid requirement, or (2) a decrease of ≥ 30% or ≥ 2 points on the NRS from the baseline with simultaneously reduced opioid consumption after NCPB. Logistic regression analysis was performed to determine the factors associated with successful responses to NCPB.
Results:
Among the 513 patients included in the analysis, 255 (49.8%) and 258 (50.2%) patients were in the non-responder and responder group after NCPB, respectively. Multivariable logistic regression analysis showed that diabetes (odds ratio [OR] = 0.644, P = 0.035), history of upper abdominal surgery (OR = 0.691, P = 0.040), and celiac metastasis (OR = 1.496, P = 0.039) were the independent factors associated with response to NCPB.
Conclusions
Celiac plexus metastases, absence of diabetes, and absence of prior upper abdominal surgery may be independently associated with better response to NCPB for upper abdominal cancer-related pain.
8.Factors associated with successful response to neurolytic celiac plexus block in patients with upper abdominal cancer-related pain: a retrospective study
Hyun-Jung KWON ; Kyunghwan JANG ; Jeong-Gil LEEM ; Jin-Woo SHIN ; Doo-Hwan KIM ; Seong-Soo CHOI
The Korean Journal of Pain 2021;34(4):479-486
Background:
Prior studies have reported that 40%-90% of the patients with celiac plexus-mediated visceral pain benefit from the neurolytic celiac plexus block (NCPB), but the predictive factors of response to NCPB have not been evaluated extensively. This study aimed to identify the factors associated with the immediate analgesic effectiveness of NCPB in patients with intractable upper abdominal cancer-related pain.
Methods:
A retrospective review was performed of 513 patients who underwent NCPB for upper abdominal cancer-related pain. Response to the procedure was defined as (1) a decrease of ≥ 50% or ≥ 4 points on the numerical rating scale (NRS) in pain intensity from the baseline without an increase in opioid requirement, or (2) a decrease of ≥ 30% or ≥ 2 points on the NRS from the baseline with simultaneously reduced opioid consumption after NCPB. Logistic regression analysis was performed to determine the factors associated with successful responses to NCPB.
Results:
Among the 513 patients included in the analysis, 255 (49.8%) and 258 (50.2%) patients were in the non-responder and responder group after NCPB, respectively. Multivariable logistic regression analysis showed that diabetes (odds ratio [OR] = 0.644, P = 0.035), history of upper abdominal surgery (OR = 0.691, P = 0.040), and celiac metastasis (OR = 1.496, P = 0.039) were the independent factors associated with response to NCPB.
Conclusions
Celiac plexus metastases, absence of diabetes, and absence of prior upper abdominal surgery may be independently associated with better response to NCPB for upper abdominal cancer-related pain.
9.Fasting blood glucose and the risk of all-cause mortality in patients with diabetes mellitus undergoing hemodialysis
Soo-Young YOON ; Jin Sug KIM ; Gang Jee KO ; Yun Jin CHOI ; Ju Young MOON ; Kyunghwan JEONG ; Hyeon Seok HWANG
Kidney Research and Clinical Practice 2024;43(5):680-689
Glycemic control is particularly important in hemodialysis (HD) patients with diabetes mellitus (DM). Although fasting blood glucose (FBG) level is an important indicator of glycemic control, a clear target for reducing mortality in HD patients with DM is lacking. Methods: A total of 26,162 maintenance HD patients with DM were recruited from the National Health Insurance Database of Korea between 2002 and 2018. We analyzed the association of FBG levels at the baseline health examination with the risk of all-cause and cause-specific mortality. Results: Patients with FBG 80–100 mg/dL showed a higher survival rate compared with that of other FBG categories (p < 0.001). The risk of all-cause mortality increased with the increase in FBG levels, and adjusted hazard ratios (HRs) were 1.10 (95% confidence interval [CI], 1.04–1.17), 1.21 (95% CI, 1.13–1.29), 1.36 (95% CI, 1.26–1.46), and 1.61 (95% CI, 1.51–1.72) for patients with FBG 100–125, 125–150, 150–180, and ≥180 mg/dL, respectively. The HR for mortality was also significantly increased in patients with FBG <80 mg/dL (adjusted HR, 1.14; 95% CI, 1.05–1.23). The analysis of cause-specific mortality also revealed a J-shaped curve between FBG levels and the risk of cardiovascular deaths. However, the risk of infection or malignancy-related deaths was not linearly increased as FBG levels increased. Conclusion: A J-shaped association was observed between FBG levels and the risk of all-cause mortality, with the lowest risk at FBG 80–100 mg/dL in HD patients with DM.
10.Fasting blood glucose and the risk of all-cause mortality in patients with diabetes mellitus undergoing hemodialysis
Soo-Young YOON ; Jin Sug KIM ; Gang Jee KO ; Yun Jin CHOI ; Ju Young MOON ; Kyunghwan JEONG ; Hyeon Seok HWANG
Kidney Research and Clinical Practice 2024;43(5):680-689
Glycemic control is particularly important in hemodialysis (HD) patients with diabetes mellitus (DM). Although fasting blood glucose (FBG) level is an important indicator of glycemic control, a clear target for reducing mortality in HD patients with DM is lacking. Methods: A total of 26,162 maintenance HD patients with DM were recruited from the National Health Insurance Database of Korea between 2002 and 2018. We analyzed the association of FBG levels at the baseline health examination with the risk of all-cause and cause-specific mortality. Results: Patients with FBG 80–100 mg/dL showed a higher survival rate compared with that of other FBG categories (p < 0.001). The risk of all-cause mortality increased with the increase in FBG levels, and adjusted hazard ratios (HRs) were 1.10 (95% confidence interval [CI], 1.04–1.17), 1.21 (95% CI, 1.13–1.29), 1.36 (95% CI, 1.26–1.46), and 1.61 (95% CI, 1.51–1.72) for patients with FBG 100–125, 125–150, 150–180, and ≥180 mg/dL, respectively. The HR for mortality was also significantly increased in patients with FBG <80 mg/dL (adjusted HR, 1.14; 95% CI, 1.05–1.23). The analysis of cause-specific mortality also revealed a J-shaped curve between FBG levels and the risk of cardiovascular deaths. However, the risk of infection or malignancy-related deaths was not linearly increased as FBG levels increased. Conclusion: A J-shaped association was observed between FBG levels and the risk of all-cause mortality, with the lowest risk at FBG 80–100 mg/dL in HD patients with DM.